BTIG has increased its 12-month price target on GE HealthCare (NASDAQ:GEHC) to $91.00 from $87.00 while retaining a Buy rating after the company released fourth-quarter 2025 results that outperformed both BTIG and broader Street estimates.
GE HealthCare reported revenue of $5.698 billion, a 7.1% increase year-over-year, and organic revenue growth of 4.8%. Those top-line figures exceeded BTIG's estimate of $5.478 billion and the consensus forecast of $5.613 billion. Adjusted earnings per share for the quarter were $1.44, ahead of BTIG's $1.38 estimate and the consensus number of $1.40.
Orders expanded by roughly 2.0% in the quarter, producing a book-to-bill ratio of 1.06x. That order growth represents a softer comparison to fourth-quarter 2024, when orders rose 5.9% year-over-year. Segment performance was mixed: Pharmaceutical Diagnostics, Imaging, and Ultrasound outperformed expectations while Patient Care Solutions came in slightly below what analysts anticipated.
Looking ahead to fiscal 2026, GE HealthCare provided guidance for approximately 3.0%-4.0% organic revenue growth, an adjusted EBIT margin range of 15.8%-16.1% - characterized by management as a 50-80 basis point improvement - and adjusted earnings per share of $4.95-$5.15. BTIG observed that the midpoint of the organic revenue guidance is about 30-40 basis points beneath consensus estimates, while the earnings outlook slightly exceeds the Street projection of $4.94.
BTIG also flagged the company’s first-quarter 2026 guidance, which calls for 2%-3% organic revenue growth. In its commentary, the brokerage noted that GE HealthCare’s capacity to manage tariff headwinds and to drive margin expansion should underpin adjusted EPS as the company pursues its mid-term targets.
Additional reporting from GE HealthCare Technologies Inc. on the same quarter noted a 3.5% increase in organic revenue and emphasized strategic innovations and operational improvements that contributed to steady performance. The company highlighted ongoing efforts to refine its operations and product portfolio, and the earnings release did not trigger any specific upgrades or downgrades from major firms in the wake of results.
Investor reaction was reflected in premarket trading, where confidence in the company’s outlook was visible. Collectively, the results and guidance signal management’s intent to hold a course of measured revenue expansion while improving margins and delivering higher adjusted earnings-per-share in fiscal 2026.
For stakeholders in healthcare equipment and diagnostics markets, the report provides concrete data points on volume and margin trends as GE HealthCare navigates headwinds such as tariffs and varying demand across product segments.